Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.
Advanced therapies
Biologics
Crohn’s disease
Dose escalation
Ulcerative colitis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
02
12
2022
accepted:
10
02
2023
medline:
17
5
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Dose escalation is one of the treatment approaches studied and suggested in advanced therapies for Crohn's disease (CD) and ulcerative colitis (UC). This study aimed to identify and characterize the dosing escalation patterns of advanced therapies in CD and UC. Two systematic literature reviews (SLRs) were conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. MEDLINE Among 3190 CD and 2116 UC articles identified in the Ovid searches, 100 CD and 54 UC studies were included in the SLR, with more studies conducted ONA. Most studies reported an initial maintenance dose pattern aligned with the lower starting dose per local regulatory label; however, several ONA studies (n = 13 out of 14) reported ustekinumab every 8 weeks as starting maintenance pattern in CD. In ONA studies, the median within-guideline escalation rates in CD and UC were 43% in ustekinumab (CD only), 33% and 32% for vedolizumab; 29% and 39% for adalimumab; and 14% and 10% for infliximab. Evidence regarding dose escalation patterns for tofacitinib, certolizumab pegol, and golimumab was limited. Some dose escalation patterns outside of label recommendations were observed including ustekinumab every 8 weeks to every 4 weeks and vedolizumab every 8 weeks to every 6 weeks. Dose escalation strategies are widely documented in the literature. The reported dose escalation patterns and escalation rates vary by region and by CD and UC. Most escalation patterns reported were aligned with regulatory recommendations while some reported more diverse or aggressive dose escalation. CRD42021289251.
Identifiants
pubmed: 36930430
doi: 10.1007/s12325-023-02457-6
pii: 10.1007/s12325-023-02457-6
pmc: PMC10129944
doi:
Substances chimiques
Ustekinumab
FU77B4U5Z0
Adalimumab
FYS6T7F842
Infliximab
B72HH48FLU
Types de publication
Systematic Review
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2051-2081Informations de copyright
© 2023. The Author(s).
Références
Bernstein CN, et al. World gastroenterology organisation global guidelines inflammatory bowel disease: update august 2015. J Clin Gastroenterol. 2016;50(10):803–18.
pubmed: 27741097
doi: 10.1097/MCG.0000000000000660
Denson LA, et al. Challenges in IBD research: precision medicine. Inflamm Bowel Dis. 2019;25(Suppl 2):S31–9.
pubmed: 31095701
doi: 10.1093/ibd/izz078
Tabib NSS, et al. Big data in IBD: big progress for clinical practice. Gut. 2020;69(8):1520–32.
doi: 10.1136/gutjnl-2019-320065
Alatab S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30.
doi: 10.1016/S2468-1253(19)30333-4
Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc. 2014;89(11):1553–63.
pubmed: 25199861
doi: 10.1016/j.mayocp.2014.07.002
Feuerstein JD, Cheifetz AS. Crohn disease: epidemiology, diagnosis, and management. Mayo Clin Proc. 2017;92(7):1088–103.
pubmed: 28601423
doi: 10.1016/j.mayocp.2017.04.010
Dignass A, et al. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ. 2020;23(4):415–27.
pubmed: 31858853
doi: 10.1080/13696998.2019.1707210
da Silva BC, et al. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014;20(28):9458–67.
pubmed: 25071340
pmcid: 4110577
doi: 10.3748/wjg.v20.i28.9458
Crohn's & Colitis Foundation of America. The facts about Inflammatory Bowel Diseases. 2014.
Cohen R, et al. Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US. J Med Econ. 2015;18(6):447–56.
pubmed: 25728698
doi: 10.3111/13696998.2015.1021353
Ananthakrishnan AN, Kaplan GG, Ng SC. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin Gastroenterol Hepatol. 2020;18(6):1252–60.
pubmed: 32007542
doi: 10.1016/j.cgh.2020.01.028
Matos R, et al. Quality of life in patients with inflammatory bowel disease: the role of positive psychological factors. Health Psychol Behav Med. 2021;9(1):989–1005.
pubmed: 34868738
pmcid: 8635588
doi: 10.1080/21642850.2021.2007098
Mayo Clinic. Crohn's disease. 2020 [cited 2022 February 15]; Available from: https://www.mayoclinic.org/diseases-conditions/crohns-disease/symptoms-causes/syc-20353304
Cleveland Clinic. Ulcerative Colitis. 2020 [cited 2022 February 15]; Available from: https://my.clevelandclinic.org/health/diseases/10351-ulcerative-colitis
Click B, Binion DG, Anderson AM. Predicting costs of care for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(3):393–5.
pubmed: 27923719
doi: 10.1016/j.cgh.2016.11.027
Annese V, et al. Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therap Adv Gastroenterol. 2021;14:17562848211065328.
pubmed: 34987611
pmcid: 8721421
doi: 10.1177/17562848211065329
Ehrenberg R., et al. Dose escalation assessment among targeted immunomodulators in the management of inflammatory bowel disease. J Manag Care Spec Pharm. 2020;26(6): 758–765
van der Valk ME, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut. 2014;63(1):72–9.
pubmed: 23135759
doi: 10.1136/gutjnl-2012-303376
Lichtenstein, GR, et al. Lifetime economic burden of Crohn's disease and ulcerative colitis by age at diagnosis. Clin Gastroenterol Hepatol. 2020;18(4): 889–897 e10.
Gibson TB, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261–2122.
pubmed: 19001952
doi: 10.1097/JOM.0b013e318181b8ca
Rubin DT, et al. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn’s disease. Aliment Pharmacol Ther. 2014;39(10):1143–55.
pubmed: 24697826
doi: 10.1111/apt.12727
Long MD, et al. Retrospective database analysis: dose escalation and adherence in patients initiating biologics for ulcerative colitis. Dig Dis. 2021;40(5):553–64.
pubmed: 34879378
doi: 10.1159/000521299
Guberna L., et al. Frequency and effectiveness of empirical anti-tnf dose intensification in inflammatory bowel disease: systematic review with meta-analysis. J Clin Med, 2021. 10(10).
Khan S, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495–507.
pubmed: 30873648
Zittan E, Gralnek IM, Berns MS. The new proactive approach and precision medicine in Crohn's disease. Biomedicines. 2020;8(7).
Sanchez-Hernandez JG, et al. A 3-year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. Br J Clin Pharmacol. 2020;86(6):1165–75.
pubmed: 32022291
pmcid: 7256129
doi: 10.1111/bcp.14229
Ma C, et al. Ustekinumab effective for maintaining clinical response in refractory moderate-to-severe Crohn’s disease: a multicentre cohort study [abstract]. In: Journal of the Canadian Association of Gastroenterology. Oxford University Press; 2018. p. 182–4.
Eberl A, et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019;54(6):718–25.
pubmed: 31184512
doi: 10.1080/00365521.2019.1624817
Yadav A, et al. Dose escalation (Q4) of ustekinumab should be considered for Crohn's disease patients who fail standard dosing [abstract]. In: Inflammatory bowel diseases. 2020, Crohn’s & Colitis Foundation and the AGA Institute. p. S72–S73.
Battat R, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2017; 15(9): 1427–1434 e2.
Heron V, et al. Ustekinumab therapeutic drug monitoring in Crohn’s disease patients with loss of response. J Crohns Colitis. 2019;13:S379–80.
doi: 10.1093/ecco-jcc/jjy222.657
Olmedo-Martín R, et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy: an observational multicentre study. J Crohns Colitis. 2021;15:S467–8.
doi: 10.1093/ecco-jcc/jjab076.601
Mateos B, et al. Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn’s Disease patients. J Crohns Colitis. 2021;15:S533–4.
doi: 10.1093/ecco-jcc/jjab076.697
Ma C, et al. Long-term maintenance of clinical, endoscopic, and radiographic response to ustekinumab in moderate-to-severe Crohn’s disease: real-world experience from a multicenter cohort study. Inflamm Bowel Dis. 2017;23(5):833–9.
pubmed: 28328624
doi: 10.1097/MIB.0000000000001074
Khorrami S, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–9.
pubmed: 27306072
doi: 10.1097/MIB.0000000000000842
Chaparro M, et al. Long-term durability and safety of Ustekinuman (UST) in patients with active Crohn's disease (CD) in real life: SUSTAIN study [abstract]. In: 28th United European Gastroenterology Week. 2020: Virtual. 407–408.
Chaparro M, et al. Effectiveness and safety of Ustekinumab (UST) in patients with active Crohn's disease (CD) in real life: SUSTAIN study [abstract]. In: 28th United European Gastroenterology Week. 2020: Virtual. 406–407.
Truyens M, et al. Efficacy of Ustekinumab intensification and re-induction in Crohn’s disease patients with insufficient or loss of response. Unit Eur Gastroenterol J. 2019;7(8 suppl): 645–645
Glassner K, et al. Low levels of ustekinumab despite dose escalation is a risk factor for surgery. Am Coll Gastroenterol. 2019;114:S405.
Ramaswamy PK, et al. MO1869 Efficacy of dose intensification of ustekinumab in Crohn's disease. Gastroenterology. 2020;S-956.
Sipponen T, et al. A nationwide real-world study on dynamic ustekinumab dosing and concomitant medication use among Crohn’s disease patients in Finland. Scand J Gastroenterol. 2021;56(6):661–70.
pubmed: 33820465
doi: 10.1080/00365521.2021.1906315
Biemans VBC, et al. Vedolizumab for inflammatory bowel disease: two-year results of the initiative on Crohn and Colitis (ICC) registry, a nationwide prospective observational cohort study. Clin Pharmacol Ther. 2020;107:1189–99.
pubmed: 31677154
doi: 10.1002/cpt.1712
Biemans V, et al. Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study. J Crohns Colitis. 2019;13:S363–4.
doi: 10.1093/ecco-jcc/jjy222.627
Attauabi M, et al. Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease—a real-world two-center cohort study. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1): e709-e718.
Attauabi M, et al. Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease—a real-world two-center cohort study [abstract]. In: 29th United European Gastroenterology Week. 2021:550.
Shivashankar R, et al. Effect of vedolizumab dose escalation on recapturing response in patients with inflammatory bowel disease. Gastroenterol. 2017;152(5).
Mendoza Ladd AH, et al. Sa1086 Dose Escalation of Vedolizumab From Every 8 Weeks to Every 4 or 6 Weeks Enables Patients With Inflammatory Bowel Disease to Recapture Response. In: Gastroenterology. 2016:S235-S236.
Iborra M, et al. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Gastroenterología y Hepatología (English Edition). 2018;41(9):535–43.
doi: 10.1016/j.gastre.2018.11.007
Iborra M, et al. Vedolizumab, an adequate option in medically refractory and thiopurine-intolerant inflammatory bowel disease patients. J Crohns Colitis. 2018;12:S472–3.
doi: 10.1093/ecco-jcc/jjx180.841
Dulai PS, et al. The real-world effectiveness and safety of vedolizumab for moderate-severe Crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111(8):1147–55.
pubmed: 27296941
doi: 10.1038/ajg.2016.236
Amiot A, et al. One-year effectiveness and safety of Vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46(3):310–21.
pubmed: 28593685
doi: 10.1111/apt.14167
Amiot A, et al. Three-year effectiveness and safety of Vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50(1):40–53.
pubmed: 31165509
doi: 10.1111/apt.15294
Srinivasan A, et al. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn’s disease. Aliment Pharmacol Ther. 2020;51(12):1342–52.
pubmed: 32379358
doi: 10.1111/apt.15742
Suzuki T, et al. Adalimumab dose escalation therapy is effective in refractory Crohn’s disease patients with loss of response to adalimumab, especially in cases without previous infliximab treatment. Case Rep Gastroenterol. 2019;13(1):37–49.
pubmed: 31182942
pmcid: 6547276
doi: 10.1159/000496453
Olivares D, et al. Differences in the need for Adalimumab dose optimization between Crohn’s disease and Ulcerative Colitis. Rev Esp Enferm Dig. 2019;111(11):846–51.
pubmed: 31566410
Olivares D, et al. Need for adalimumab dose optimization in patients with Crohn's disease and ulcerative Colitis [abstract]. In: 26th United European Gastroenterology Week. 2018: Vienna, Austria, p. A454.
Kanazawa J, et al. Long-term outcomes of adalimumab in patients with Crohn’s disease: can a doubled dose of adalimumab improve outcomes? J Crohns Colitis. 2019;13:S367–8.
doi: 10.1093/ecco-jcc/jjy222.633
Papamichael K, et al., Primary Non Response to Infliximab in Patients With Inflammatory Bowel Disease. AGA. 2014: S-457.
Castaño-Milla C, et al. Effectiveness of adalimumab in perianal fistulas in Crohn’s disease patients naive to Anti-TNF therapy. J Clin Gastroenterol. 2015;49(1):34–40.
pubmed: 25485513
doi: 10.1097/MCG.0000000000000169
Castaño-Milla C, et al. Effectiveness of adalimumab in the treatment of perianal fistulas in patients with Crohn's disease naïve to anti-TNF: a multicenter study [abstract]. In: 7th Congress of ECCO - the European Crohn's and Colitis Organisation. 2012: Barcelona, Spain. p. S155.
Roblin X, et al. Swapping versus dose optimization in patients losing response to adalimumab with adequate drug levels. Inflamm Bowel Dis. 2021.
Seo H, et al. Long-term outcomes of adalimumab treatment in 254 patients with Crohn’s disease: a hospital-based cohort study from Korea. Dig Dis Sci. 2017;62(10):2882–93.
pubmed: 28822006
doi: 10.1007/s10620-017-4715-7
Preda C, et al. Adalimumab and Infliximab in Crohn’s disease—real life data from a national retrospective cohort study. Curr Health Sci J. 2016;42(2):115–24.
pubmed: 30568821
pmcid: 6256158
Fulger LE, et al. Infliximab and adalimumab in Crohn's disease: a comparative analysis of efficacy, safety and management of secondary loss of response in a cohort Romanian study [abstract]. In: 23rd United European Gastroenterology Week. 2015: Barcelona, Spain. p. A431.
Kariyawasam VC, et al. Thiopurines dosed to a therapeutic 6-thioguanine level in combination with adalimumab are more effective than subtherapeutic thiopurine-based combination therapy or adalimumab monotherapy during induction and maintenance in patients with long-standing Crohn’s disease. Inflamm Bowel Dis. 2017;23(9):1555–65.
pubmed: 28786865
doi: 10.1097/MIB.0000000000001183
Viazis N, et al. Azathioprine discontinuation earlier than 6 months in Crohn’s disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. Eur J Gastroenterol Hepatol. 2015;27(4):436–41.
pubmed: 25874518
doi: 10.1097/MEG.0000000000000303
Archavlis E, et al. Adalimumab for patients with Crohn's disease and secondary loss of response or severe allergy to Infliximab. [abstract]. In: 6th Congress of ECCO—European Crohn’s and Colitis Organisation. 2011: Dublin, Ireland. p. S86.
Ghaly S, et al. Dose tailoring of anti-tumour necrosis factor-alpha therapy delivers useful clinical efficacy in Crohn disease patients experiencing loss of response. Intern Med J. 2015;45(2):170–7.
pubmed: 25370691
doi: 10.1111/imj.12621
Ma C, et al. Adalimumab dose escalation is effective for managing secondary loss of response in Crohn’s disease. Aliment Pharmacol Ther. 2014;40(9):1044–55.
pubmed: 25185992
doi: 10.1111/apt.12940
Duveau N, et al. Adalimumab dose escalation is effective and well tolerated in Crohn’s disease patients with secondary loss of response to Adalimumab. In: 11th Congress of ECCO—European Crohn's and Colitis Organisation. 2016: Amsterdam, The Netherlands. p. S320.
Guerbau L, et al. Crohn's disease patients with high body mass index present more frequent and rapid loss of response to Infliximab [abstract]. In: 11th Congress of ECCO – European Crohn´s and Colitis Organisation. 2016: Amsterdam, The Netherlands. p. S430.
Bhalme M, et al. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn’s disease? Eur J Gastroenterol Hepatol. 2013;25(5):543–9.
pubmed: 23337170
doi: 10.1097/MEG.0b013e32835d1f15
Sakuraba A, et al. Combination therapy with infliximab and thiopurine compared to infliximab monotherapy in maintaining remission of postoperative Crohn’s disease. Digestion. 2015;91(3):233–8.
pubmed: 25823572
doi: 10.1159/000375302
Park SH, et al. Long-term outcomes of infliximab treatment in 582 korean patients with Crohn’s disease: a hospital-based cohort study. Dig Dis Sci. 2016;61(7):2060–7.
pubmed: 26971089
doi: 10.1007/s10620-016-4105-6
Park SH, et al. Long-term outcome of infliximab treatment in patients with Crohn’s disease: a hospital-based cohort study from Korea [abstract]. In: 10th Congress of ECCO—European Crohn’s and Colitis Organisation. Spain: Barcelona; 2015. p. S57–8.
Dreesen E, et al. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn’s disease who lose clinical response. Aliment Pharmacol Ther. 2018;47(3):346–55.
pubmed: 29226370
doi: 10.1111/apt.14452
Katz L, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn’s disease patients with loss of response. Inflamm Bowel Dis. 2012;18(11):2026–33.
pubmed: 22294554
doi: 10.1002/ibd.22902
Lin KK, et al. Durability of infliximab dose intensification in Crohn’s disease. Dig Dis Sci. 2012;57(4):1013–9.
pubmed: 22089254
doi: 10.1007/s10620-011-1969-3
Komaki Y, et al. Infliximab therapy intensification based on endoscopic activity is related to suppress treatment discontinuation in patients with Crohn disease: a retrospective cohort study. Med (Baltim). 2021;100(6): e24731.
doi: 10.1097/MD.0000000000024731
Chaparro M, et al. Intensification of infliximab therapy in Crohn’s disease: efficacy and safety. J Crohns Colitis. 2012;6(1):62–7.
doi: 10.1016/j.crohns.2011.07.005
Chaparro M, et al. Long-term durability of Infliximab treatment in Crohn's disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol. 2011;45(2): 113–118.
Kopylov U, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of Infliximab. Aliment Pharmacol Ther. 2011;33(3):349–57.
pubmed: 21118397
doi: 10.1111/j.1365-2036.2010.04523.x
Nagata Y, et al. Therapeutic strategy for Crohn’s disease with a loss of response to infliximab: a single-center retrospective study. Digestion. 2015;91(1):50–6.
pubmed: 25632918
doi: 10.1159/000368815
Guerbau L, et al. Patients with Crohn’s disease with high body mass index present more frequent and rapid loss of response to infliximab. Inflamm Bowel Dis. 2017;23(10):1853–9.
pubmed: 28837519
doi: 10.1097/MIB.0000000000001179
Maemoto A, et al. Mo1263 CRP, but Not CDAI is associated with enterocolonic mucosal healing in crohn's disease treated with infliximab; a single center cohort study. In: Gastrointestinal Endoscopy. 2012.
Moon W, et al. Efficacy and safety of certolizumab pegol for Crohn’s disease in clinical practice. Aliment Pharmacol Ther. 2015;42(4):428–40.
pubmed: 26081839
doi: 10.1111/apt.13288
Moon W, et al. Effectiveness and safety of certolizumab pegol for Crohn's disease in a large cohort followed at a tertiary care center [abstract]. In: 46th Annual Digestive Disease Week (DDW). 2015:S-871.
Haider SA, et al. Ustekinumab dose escalation improves clinical responses in refractory Crohn’s disease. Therap Adv Gastroenterol. 2020;13:1756284820959245.
pubmed: 33133239
pmcid: 7576911
doi: 10.1177/1756284820959245
Ollech JE, et al. Effectiveness of ustekinumab dose escalation in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2021;19(1):104–10.
pubmed: 32109634
doi: 10.1016/j.cgh.2020.02.035
Ding Z, et al. Real-world persistence, maintenance dosing, and pre-post corticosteroid and opioid use among Crohn’s disease patients with prescription claims for ustekinumab in the USA. Drugs Real World Outcomes. 2021;8(4):565–75.
pubmed: 34136998
pmcid: 8605940
doi: 10.1007/s40801-021-00264-5
Muser E, et al. Treatment persistence and maintenance dosing for Ustekinumab and Adalumumab among patients with Crohn's disease with 2-years follow-up in the Symphony health database [abstract]. In: 2020 Digestive Disease Week (DDW) 2020: Virtual. p. S959.
Dalal RS, et al. Predictors of ustekinumab failure after dose intensification among patients with Crohn’s disease [abstract]. In: 2020 ACG Annual Meeting. Tennessee: Nashville; 2020. p. S324–5.
Nije C, Dalal RS, Allegretti JR. Factors Associated With Ustekinumab Dose Escalation in Patients With Crohn’s Disease [abstract]. In: 2020 ACG Annual Meeting, Nashville, Tennessee. p. S368. 2020
Greenup AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017;52(12):1354–9.
pubmed: 28885058
doi: 10.1080/00365521.2017.1373847
Kopylov U, et al. Subcutaneous Ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014;8(11):1516–22.
pubmed: 24996483
doi: 10.1016/j.crohns.2014.06.005
Dalal RS, et al. Ustekinumab Dose Intensification in Patients With Crohn’s Disease: Comparing Every 4 and Every 6-Week Dosing [abstract]. In: 2020 ACG Annual Meeting.Nashville, Tennessee. p. S414. 2020
Obando C, et al. Persistence, dose titration, and health care resource utilization among Crohn’s disease patients treated with ustekinumab: a real-world analysis in the United States. Adv Ther. 2020;37(5):2127–43.
pubmed: 32193810
pmcid: 7467496
doi: 10.1007/s12325-020-01276-3
Hanzel J, et al. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn’s disease. Eur J Gastroenterol Hepatol. 2021;33(1S):e831–6.
pubmed: 34402470
doi: 10.1097/MEG.0000000000002275
Kiat C, et al. Ustekinumab in Crohn’s disease: experience from a single tertiary centre. Ir J Med Sci. 2015;184:S245.
Kopylov U, et al. Effectiveness of Ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020;52(1):135–42.
pubmed: 32412134
doi: 10.1111/apt.15784
Kopylov U, et al. Effectiveness of dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous Ustekinumab maintenance therapy: a multicentre international cohort study [abstract]. In: 15th Congress of ECCO—European Crohn’s and Colitis Organisation. Austria: Vienna; 2020. p. S111–2.
Iborra M, et al. Real-world long-term effectiveness of Ustekinumab in Crohn's disease: Results from the ENEIDA registry [abstract]. In: Digestive disease week (DDW) 2020. Virtual. p. S953. 2020
Townsend T, et al. Comparative effectiveness of Ustekinumab or Vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn’s disease. Aliment Pharmacol Ther. 2020;52(8):1341–52.
pubmed: 32955122
Biemans V, et al. Ustekinumab for Crohn’s disease: results of the ICC registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2019;14(1):33–45.
pmcid: 7142409
doi: 10.1093/ecco-jcc/jjz119
European Medicines Agency. Janssen Biologics B.V. STELARA (ustekinumab) [package insert]. 2013 [cited 2022 February 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf
Wice M, et al. Efficacy and safety of vedolizumab in patients with inflammatory bowel disease in a large tertiary medical center. Am J Gastroenterol. 2016;111:S270.
doi: 10.14309/00000434-201610001-00588
Reinglas J, et al. Low rate of drug discontinuation, frequent need for dose adjustment, and no association with development of new arthralgia in patients treated with vedolizumab: results from a tertiary referral IBD center. Dig Dis Sci. 2020;65(7):2046–53.
pubmed: 31813132
doi: 10.1007/s10620-019-05982-z
Williet N, et al. Association between low trough levels of vedolizumab during induction therapy for inflammatory bowel diseases and need for additional doses within 6 months. Clin Gastroenterol Hepatol. 2017;15(11): 1750–1757 e3
Lee SD, Singla A, Clark-Snustad K. Standard and modified Vedolizumab dosing is effective in achieving clinical and endoscopic remission in moderate-severe Crohn’s disease. GastroHep. 2021;3(1):26–36.
doi: 10.1002/ygh2.438
Dreesen E, et al. Evidence to support monitoring of vedolizumab trough concentrations in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2018;16(12): 1937–1946 e8.
Lee SD, et al. Real-world experience: clinical and endoscopic effectiveness of standard Vedolizumab dosing and modified maintenance dosing in patients with moderate to severe Crohn's disease [abstract]. In: 2020 Digestive Disease Week (DDW). Virtual. p. S-961–S-962. 2020
Restellini S, et al. Therapeutic drug monitoring guides the management of Crohn’s patients with secondary loss of response to adalimumab. Inflamm Bowel Dis. 2018;24(7):1531–8.
pubmed: 29668893
doi: 10.1093/ibd/izy044
Peters CP, et al. Adalimumab for Crohn’s disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis. 2014;8(8):866–75.
pubmed: 24491515
doi: 10.1016/j.crohns.2014.01.012
Monfared AAT, Fan T, Sen S. Dose Escalation of Adalimumab (Humira1)in Patients with Crohn’s Disease in Routine Clinical Practice in Quebec [abstract], in 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Chicago, Illinois. p. S180. 2011
Mantzaris GJ, et al. Factors influencing the time to and outcome of dose escalation of Adalimumab in Crohn’s disease patients who achieved steroid-free remission on Adalimumab. In: 9th Congress of ECCO—the European Crohn’s and Colitis Organisation. Denmark: Copenhagen; 2014. p. S269–70.
Aguas M, et al. Adalimumab in prevention of postoperative recurrence of Crohn’s disease in high-risk patients. World J Gastroenterol. 2012;18(32):4391–8.
pubmed: 22969204
pmcid: 3436056
doi: 10.3748/wjg.v18.i32.4391
Fortea-Ormaechea JI, et al. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn’s disease. The madrid experience. Gastroenterol Hepatol. 2011;34(7):443–8.
pubmed: 21724297
doi: 10.1016/j.gastrohep.2011.04.001
Mastronardi M, et al. Administration timing is the best clinical outcome predictor for adalimumab administration in Crohn’s disease. Front Med (Lausanne). 2019;6:234.
pubmed: 31737635
doi: 10.3389/fmed.2019.00234
Verstockt B, et al. Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn’s disease patients: the usefulness of rapid testing. Aliment Pharmacol Ther. 2018;48(7):731–9.
pubmed: 30109889
doi: 10.1111/apt.14943
Reenaers C, et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn’s disease treated with adalimumab? Aliment Pharmacol Ther. 2012;36(11–12):1040–8.
pubmed: 23061650
doi: 10.1111/apt.12076
Baert F, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn’s patients. J Crohns Colitis. 2013;7(2):154–60.
pubmed: 22537637
doi: 10.1016/j.crohns.2012.03.018
Orlando A, et al. Adalimumab in steroid-dependent Crohn’s disease patients: prognostic factors for clinical benefit. Inflamm Bowel Dis. 2012;18(5):826–31.
pubmed: 21837774
doi: 10.1002/ibd.21835
Barberio B, et al. Infliximab originator, infliximab biosimilar, and adalimumab are more effective in Crohn’s disease than ulcerative colitis: a real-life cohort study. Clin Transl Gastroenterol. 2020;11(5): e00177.
pubmed: 32677808
pmcid: 7263644
doi: 10.14309/ctg.0000000000000177
O’Donnell S, et al. Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn’s disease. J Crohns Colitis. 2015;9(10):830–6.
pubmed: 26116556
doi: 10.1093/ecco-jcc/jjv115
O'Donnell S, Stempak JM, Silverberg MS. Is there a higher rate of infliximab dose optimization in initial responders between UC and CD cases? [abstract]. In: 2014 Digestive Disease Week (DDW). Chicago, Illinois. p. S-462–S-463. 2014
Tkacz J, et al. Infliximab dosing patterns in a sample of patients with Crohn’s disease: results from a medical chart review. Am Health Drug Benefits. 2014;7:87–93.
pubmed: 24991393
pmcid: 4049116
Waters H, et al. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review. J Med Econ. 2011;14(4):397–402.
pubmed: 21595522
doi: 10.3111/13696998.2011.583152
Clark-Snustad KD, Singla A, Lee SD. Efficacy of Infliximab in Crohn’s disease patients with prior primary-nonresponse to tumor necrosis factor antagonists. Dig Dis Sci. 2019;64(7):1952–8.
pubmed: 30815825
doi: 10.1007/s10620-019-05490-0
Kato M, et al. Long-term outcomes of infliximab therapy for patients with Crohn's disease at different time of initiation of infliximab administration: a single-centre cohort study in Japan [abstract]. In: United European Gastroenterology Week. Barcelona, Spain. p. 351. 2019
Tanaka H, et al. Long-term outcomes of infliximab therapy for japanese patients with Crohn’s disease at different times of initiation of infliximab administration [abstract]. In: 2019 Digestive Disease Week (DDW). San Diego, California. p. S-884–S-885. 2019
Mizoshita T, et al. Long-term clinical remission in biologically naive Crohn’s Disease Patients With Adalimumab Therapy, Including Analyses Of Switch From Adalimumab To Infliximab. Case Rep Gastroenterol. 2016;10(2):283–91.
pubmed: 27462198
pmcid: 4939671
doi: 10.1159/000445105
Paul S, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2013;19(12):2568–76.
pubmed: 24013361
doi: 10.1097/MIB.0b013e3182a77b41
Brandse JF, et al. Re-introduction of infliximab after consecutive failure of infliximab and adalimumab is beneficial in refractory Crohn’s disease [abstract]. In: 8th Congress of ECCO—European Crohn’s and Colitis Organisation. Austria: Vienna; 2013. p. S165–6.
Perry C, et al. Vedolizumab dose escalation improves therapeutic response in a subset of patients with ulcerative colitis. Dig Dis Sci. 2021;66(6):2051–8.
pubmed: 32710192
doi: 10.1007/s10620-020-06486-x
Perry C, et al. An evaluation of Vedolizumab “partial responders”: Quantifying benefit of shortened dosing invervals in ulverative Colitis [abstract]. In: 2020 Crohn’s and Colitis Congress. Texas: Austin; 2020. p. S70–1.
Perry C, et al. Vedolizumab dose escalation improves disease activity for “partial responders” in Ulcerative Colitis [abstract]. In: Digestive Disease Week (DDW) 2020. Virtual. p. S-965. 2020
Taxonera C, et al. Adalimumab maintenance treatment in ulcerative colitis: outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci. 2017;62(2):481–90.
pubmed: 27995400
doi: 10.1007/s10620-016-4398-5
Ferrante M, et al. Long-term outcome of infliximab therapy in patients with ulcerative colitis: identification of predictors of relapse-free and colectomy-free survival [abstract]. In: 2013 Digestive Disease Week (DDW). Orlando, Florida. p. S-426. 2013
Dumitrescu G, et al. The outcome of infliximab dose doubling in 157 patients with ulcerative colitis after loss of response to infliximab. Aliment Pharmacol Ther. 2015;42(10):1192–9.
pubmed: 26354674
doi: 10.1111/apt.13393
Taxonera C, et al. Infliximab dose escalation as an effective strategy for managing secondary loss of response in ulcerative colitis. Dig Dis Sci. 2015;60(10):3075–84.
pubmed: 26044830
doi: 10.1007/s10620-015-3735-4
Taxonera C, et al. Short- and long-term outcomes of infliximab dose intensification in patients with ulcerative colitis. In: 2012 Digestive Disease Week (DDW). San Diego, California. p. S-355. 2012
Cesarini M, et al. Dose optimization is effective in ulcerative colitis patients losing response to infliximab: a collaborative multicentre retrospective study. Dig Liver Dis. 2014;46(2):135–9.
pubmed: 24246151
doi: 10.1016/j.dld.2013.10.007
Arias MT, et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2015;13(3):531–8.
pubmed: 25117777
doi: 10.1016/j.cgh.2014.07.055
Stefanovic S, et al. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label. Eur J Gastroenterol Hepatol. 2021;33(1):54–61.
pubmed: 32804854
doi: 10.1097/MEG.0000000000001843
Taxonera C, et al. Clinical outcomes of golimumab as first, second or third anti-tnf agent in patients with moderate-to-severe ulcerative colitis. Inflamm Bowel Dis. 2017;23(8):1394–402.
pubmed: 28671873
doi: 10.1097/MIB.0000000000001144
Taxonera C, et al. Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use [abstract]. In: 11th Congress of ECCO - European Crohn's and Colitis Organisation. Amsterdam, The Netherlands. p. S303. 2016
Ollech JE, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by Vedolizumab maintenance in 71 patients with severe steroid-refractory Ulcerative Colitis. Aliment Pharmacol Ther. 2020;51(6):637–43.
pubmed: 31875986
doi: 10.1111/apt.15616
Ollech J, et al. Efficacy and safety of induction therapy with calcineurin inhibitors followed by maintenance therapy with Vedolizumab in severe Ulcerative Colitis: a large patient cohort with long-term follow-up [abstract]. In: 15th Congress of ECCO - European Crohn's and Colitis Organisation. Vienna, Austria. p. S401. 2020
European Medicines Agency. Pfizer service company BVBA. XELJANZ (tofacitinib) [package insert] 2017 March 2017. Available from: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product-information_en.pdf
Chaparro M, et al. Tofacitinib in ulcerative colitis: real world evidence from ENEIDA registry [abstract]. In: 28th United European Gastroenterology Week. Virtual. p. 419–420. 2020
Hong S, et al. Real-world effectiveness of ustekinumab in ulcerative colitis, in 2020 Crohn's & Colitis Congress. 2020: Austin, Texas. p. S120.
Dalal RS, et al. Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study. Clin Gastroenterol Hepatol. 2021.
Dalal R, et al. Predictors and outcomes of ustekinumab dose escalation to every 4 or every 6 weeks in ulcerative colitis: a multicenter cohort study in the united states [abstract]. In: 16th Congress of ECCO—European Crohn's and Colitis Organisation. Virtual. p. S296–S298. 2021
Chaparro M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(11):1846–51.
pubmed: 33860795
doi: 10.1093/ecco-jcc/jjab070
Ecker D, et al. Ustekinumab for Ulcerative Colitis a real-world experience- Retrospective data analysis of the IBD cohort Ordensklinikum Linz. In: 29th United European Gastroenterology Week. Virtual. p. 490. 2021
Almutairdi A, et al. Clinical and endoscopic remission with vedolizumab treatment in ulcerative colitis. J Crohns Colitis. 2018;12:S430–1.
doi: 10.1093/ecco-jcc/jjx180.761
Dignass A, et al. Living with ulcerative colitis in germany: estimating the frequency and extent of dose escalations among patients with moderate to severe ulcerative colitis. United Eur Gastroenterol J. 2019;7(8):341–2.
European Medicines Agency. Janssen biologics B.V. SIMPONI (golimumab) [package insert]. 2014 June 2014 [cited 2022 February 15]. Available from: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf
Kumar A, et al. Golimumab in ulcerative colitis: a multi-centre real world experience [abstract]. In: International Digestive Disease Forum (IDDF). Hong Kong. p. A83. 2018
Iborra M, et al. Real-life experience with 4 years of golimumab persistence in ulcerative colitis patients. Sci Rep. 2020;10(1):17774.
pubmed: 33082359
pmcid: 7576126
doi: 10.1038/s41598-020-73577-0
Iborra M, et al. Real-life experience with long-term maintenance of Golimumab in Ulcerative Colitis patients [abstract]. In: 14th Congress of ECCO—European Crohn’s and Colitis Organisation. Denmark: Copenhagen; 2019. p. S393–4.
Taxonera C, et al. Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis. Curr Med Res Opin. 2019;35(7):1297–304.
pubmed: 30722703
doi: 10.1080/03007995.2019.1579557
Baert F, et al. Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther. 2014;40(11–12):1324–32.
pubmed: 25277873
doi: 10.1111/apt.12968
Van de Vondel S, et al. Incidence and predictors of success of adalimumab dose escalation and de-escalation in ulcerative colitis: a real-world belgian cohort study. Inflamm Bowel Dis. 2018;24(5):1099–105.
pubmed: 29668947
doi: 10.1093/ibd/izx103
Van de Vondel S, et al. Adalimumab dose escalation and de-escalation in ulcerative colitis: incidence and predictors of success. A real life Belgian cohort study [abstract]. In: 12th Congress of ECCO—European Crohn's and Colitis Organisation. Barcelona, Spain. p. S299. 2017
Garcia-Bosch O, et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis. 2013;7(9):717–22.
pubmed: 23142005
doi: 10.1016/j.crohns.2012.10.004
Taxonera C, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther. 2011;33(3):340–8.
pubmed: 21133961
doi: 10.1111/j.1365-2036.2010.04531.x
Pollinger B, et al. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ. 2019;20(2):195–203.
pubmed: 29362899
doi: 10.1007/s10198-017-0953-z
Salomonsson S, et al. Dose escalation among ulcerative colitis patients treated with adalimumab in Sweden [abstract]. In: ISPOR 18th Annual European Congress, Milan, Italy. p. A633. 2015
Balint A, et al. Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice. J Crohns Colitis. 2016;10(1):26–30.
pubmed: 26392413
doi: 10.1093/ecco-jcc/jjv169
Shin Shin S, et al. The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea [abstract]. In: 15th COngress of ECCO - European Crohn's and Colitis Organisation, Vienna, Austria. p. S432. 2020
Choi CH, et al. The efficacy of adalimumab for the treatment of Korean patients with ulcerative colitis and predictors of response: Preliminary results [abstract]. In: 13th Congress of ECCO - European Crohn's and Colitis Organisation, Vienna, Austria. p. P477. 2018
Shah SC, et al. Accelerated infliximab dosing increases 30-day colectomy in hospitalized ulcerative colitis patients: a propensity score analysis. Inflamm Bowel Dis. 2018;24(3):651–9.
pubmed: 29462380
doi: 10.1093/ibd/izx039
Kosaraju RS, et al. Dose-intensified infliximab rescue therapy for severe ulcerative colitis does not reduce short-term colectomy rates or increase postoperative complications [abstract]. In: The American Society of Colon and Rectal Surgeons’ Annual Meeting. Washington: Seattle; 2022. p. 1232–40.
Balint A, et al. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis—results from multicenter observational cohort. Expert Opin Biol Ther. 2018;18(11):1181–7.
pubmed: 30277084
doi: 10.1080/14712598.2018.1530758
Farkas K, et al. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in Ulcerative Colitis- Results from multicentre observational cohort [abstract]. In: 25th United European Gastroenterology Week, Barcelona, Spain. p. A743. 2017
Magro F, et al. Calprotectin and the magnitude of antibodies to infliximab in clinically-stable ulcerative colitis patients are more relevant than infliximab trough levels and pharmacokinetics for therapeutic escalation. EBioMedicine. 2017;21:123–30.
pubmed: 28629912
pmcid: 5514398
doi: 10.1016/j.ebiom.2017.06.004
Fernández-Salazar L, et al. Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis. Rev Esp Enferm Dig. 2015;107:527–33.
pubmed: 26334458
Fernández-Salazar L, et al. Infliximab use in ulcerative colitis from 2003 to 2013: clinical practice, safety and efficacy [abstract]. In: 9th Congress of ECCO—the European Crohn’s and Colitis Organisation. Denmark: Copenhagen; 2014. p. S259–60.
CADTH. Biologics dose escalation for the treatment of inflammatory bowel disease: a review of clinical effectiveness, cost-effectiveness, and guidelines. Chao Y-S, Visintini S (eds) Ottawa. 2018
van der Valk ME, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11(4): e0142481.
pubmed: 27099937
pmcid: 4839678
doi: 10.1371/journal.pone.0142481
Danese S, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. Dig Dis. 2019;37(4):266–83.
pubmed: 30726845
doi: 10.1159/000496739
Gordon JP, et al. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27(7):804–12.
pubmed: 25933126
pmcid: 4892747
doi: 10.1097/MEG.0000000000000378
Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–95.
pubmed: 21366636
doi: 10.1111/j.1365-2036.2011.04612.x
Lee S, et al. Rates of treatment failure among patients with Ulcerative Colitis treated with first-line advanced treatments [abstract]. In: 29th United European Gastroenterology Week. Virtual. p. 545. 2021
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4):685–98.
pubmed: 21427713
doi: 10.1038/ajg.2011.103
Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: case series and review of literature. World J Gastroint Pharmacol Therap. 2017;8(3):155–61.
doi: 10.4292/wjgpt.v8.i3.155
Fine S, Papamichael K, Cheifetz AS. Etiology and management of lack or loss of response to anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Gastroenterol Hepatol. 2019;15(12):656–65.
Roda G, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1): e135.
pubmed: 26741065
pmcid: 4737871
doi: 10.1038/ctg.2015.63
Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015;3(1):63–8.
pubmed: 25567472
doi: 10.1093/gastro/gou087
Strand V, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316.
pubmed: 28612180
pmcid: 5548814
doi: 10.1007/s40259-017-0231-8
Rutgeerts P, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126(2):402–13.
pubmed: 14762776
doi: 10.1053/j.gastro.2003.11.014
Atreya R, Neurath MF, Siegmund B. Personalizing treatment in IBD: hype or reality in 2020? Can we predict response to anti-TNF? Front Med (Lausanne). 2020;7:517.
pubmed: 32984386
doi: 10.3389/fmed.2020.00517
Reves J, Ungaro RC, Torres J. Unmet needs in inflammatory bowel disease. Curr Res Pharmacol Drug Discov. 2021;2: 100070.
pubmed: 34988431
pmcid: 8710990
doi: 10.1016/j.crphar.2021.100070
Turner D, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570–83.
pubmed: 33359090
doi: 10.1053/j.gastro.2020.12.031
Colombel J-F, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. The Lancet. 2017;390(10114):2779–89.
doi: 10.1016/S0140-6736(17)32641-7
Panaccione R, et al. Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut. 2020;69(4):658–64.
pubmed: 31285357
doi: 10.1136/gutjnl-2019-318256
Gonczi L, et al. Clinical efficacy, drug sustainability and results from therapeutic drug monitoring in Crohn’s disease patients treated with ustekinumab—1-year follow-up of a prospective, nationwide, multicenter cohort from Hungary [abstract]. In: 16th Congress of ECCO—European Crohn's and Colitis Organisation, Virtual. p. S441. 2021
Gonczi L, et al. Clinical efficacy, drug sustainability and serum drug levels in Crohn’s disease patients treated with ustekinumab—a prospective, multicenter cohort from Hungary. Dig Liver Dis. 2022;54(2):207–13.
pubmed: 34344576
doi: 10.1016/j.dld.2021.07.008
Gubbiotti A, et al. The anti-IL-23/IL-12 agent ustekinumab is an effective and safe induction therapy in patients with crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study [abstract]. In: 15th Congress of ECCO - European Crohn's and Colitis Organisation. Vienna, Austria. p. S379. 2020
Hendler SA, et al. High-dose infliximab therapy in Crohn’s disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9(3):266–75.
pubmed: 25540149
pmcid: 6497242
doi: 10.1093/ecco-jcc/jju026
Hendler S, et al. High dose Infliximab in Crohn's disease: clinical experience, safety, and efficacy [abstract]. In: 21st United European Gastroenterology Week, Berlin, Germany. p. A522. 2013
Seo H, et al. P641 Long-term outcome of Adalimumab therapy and predictors of response in 254 patients with Crohn’s disease: a hospital-based cohort study from Korea. In: 12th Congress of ECCO—European Crohn’s and Colitis Organisation. Spain: Barcelona; 2017. p. S408–S408.
Calvo Moya M, et al. Effectiveness and evolution in the use of ustekinumab in real-life clinical practice: a single center experience with intravenous induction therapy in refractory Crohn's disease patients. In: 27th UEG Week, Barcelona, Spain. p. 636. 2019
Saiz Chumillas RM, et al. Efficacy and safety of ustekinumab in patients with Crohn’s disease refractory to anti-tumour necrosis factor: real clinical practice [abstract]. In: 16th Congress of ECCO - European Crohn's and Colitis Organisation, Virtual. p. S400–S401. 2021
Mcgregor C, et al. Real world effectiveness of ustekinumab for refractory Crohn’s disease: a regional experience [abstract]. In: 2021 British Society of Gastroenterology Annual Meeting. p. A108-A108. 2021
Gadhok R, et al. Ustekinumab: medium-term outcomes from a uk multi-centre real-world cohort [abstract]. In: 2021 British Society of Gastroenterology Annual Meeting, p. A94-A95. 2021.
Loftus EV Jr, et al. Adalimumab real-world dosage pattern and predictors of weekly dosing: patients with Crohn’s disease in the United States. J Crohns Colitis. 2011;5(6):550–4.
pubmed: 22115373
doi: 10.1016/j.crohns.2011.05.005
Kiss LS, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2011;34(8):911–22.
pubmed: 21883326
doi: 10.1111/j.1365-2036.2011.04827.x
Kiss LS, et al. Predictors of efficacy, mucosal healing and need for dose intensification at 12-months of adalimumab therapy in patients with Crohn's disease. National data from Hungary. [abstract]. J Crohn's Colitis. 2011;5: S73
Juillerat P, et al. Characteristics of patients with durable use of infliximab for 5 years. Eur J Med Sci. 2012;142:11S.
Juillerat P, et al. Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort [abstract]. In: 21st United European Gastroenterology (UEG) Week. Berlin, Germany. p. A33. 2013
Rubin D, et al. Assessment of therapy changes and drug discontinuation among Crohn’s disease patients using health claims data. Am J Gastroenterol. 2012: S681.
Gomes CF, et al. Use of bowel ultrasound to assess disease activity in Crohn’s disease patients after induction therapy with infliximab [abstract]. In: 15th Congress of ECCO - European Crohn's and Colitis Organisation, Vienna, Austria. p. S431. 2020
Osamura A, Suzuki Y. Fourteen-year anti-TNF therapy in Crohn’s disease patients: clinical characteristics and predictive factors. Dig Dis Sci. 2018;63(1):204–8.
pubmed: 29209921
doi: 10.1007/s10620-017-4846-x
Hanzel J, D’Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):399–406.
pubmed: 31760827
doi: 10.1080/14712598.2020.1697227
Taxonera C, et al. Real-life experience with golimumab in ulcerative colitis patients according to prior anti-TNF use. Gastroenterology. 2016;150:S979.
doi: 10.1016/S0016-5085(16)33318-2
Taxonera C, et al. Adalimumab dose escalation is effective for managing loss of response in ulcerative colitis [abstract]. In: 2015 Digestive Disease Week (DDW). 2015:S-789.
Pugliese D, et al. Results of interim analysis of a retrospective igibd study on adalimumab use in real practice in italy: the real-life clinical effectiveness of adalimumab in ulcerative colitis (REALADA-UC) Study [abstract],.In: 2019 Digestive Disease Week® (DDW) 2019: San Diego, California. p. S-887.